ICE Cobotics Simplifies Floor Cleaning with T IoT, From T-Mobile and Deutsche Telekom
Today, T-Mobile (NASDAQ: TMUS) announced that ICE Cobotics, a global leader in cleaning technologies and equipment, has chosen T IoT as its exclusive IoT connectivity solution worldwide to help their customers more easily manage fleets of floor cleaning robots.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005555/en/
Floor cleaning and technology company picks T IoT to power i-SYNERGY fleet management software and strengthen its global subscription service (Photo: Business Wire)
As part of the long-term agreement, T IoT — a comprehensive solution for global IoT connectivity, platform management and support — will deliver cellular connectivity to more than 7,500 new and existing ICE Cobotics intelligent and autonomous cleaning units across the world. This includes their newest product, Cobi 18, a compact autonomous floor scrubber which is designed to clean 5,000 to 7,000 square feet per hour, starting at less than $20 a day.
ICE Cobotics chose T IoT to simplify the delivery and execution of IoT solutions on a global scale, which bolsters their mission to streamline processes for its customers. Less than a year ago, the company launched an industry first: an all-inclusive subscription service for floor cleaning machines, parts and maintenance, and performance and monitoring software. The service provides customers with a more reliable, affordable, and cost predictive solution, allowing them to use their capital to expand their business versus having it tied up in equipment ownership.
T IoT supports ICE Cobotics’ subscription model by delivering cleaning performance data and insights to customers in the retail, grocery, convenience, healthcare, higher education, and hospitality industries. Imagine a major retail corporation that has hundreds of robots in service. The cellular connectivity allows a customer’s maintenance and facilities team to view their Clean Score — goal-based cleaning performance data generated by ICE Cobotics’ i-SYNERGY fleet management software. This takes the guess work out of tracking cleaning efficacy, developing efficiencies, and confirming each location is clean. Previously, they would have had to visit each store to inspect if cleaning happened, which takes time and money.
Additionally, T IoT reinforces ICE Cobotics’ commitment to eliminate downtime by delivering over the air software and firmware updates to its customers, as well as mechanical telemetry data, from sensors and cameras in each machine, back to the company. This gives them the ability to monitor and analyze critical information like hours of use, routes, temperature, and battery life — so they can determine if certain components of a machine are operating within tolerance, if service is required and if a part is near its end of life — to prevent problems before they happen.
“T IoT is critical to the success of our cleaning machines and our all-inclusive subscription service,” said Mike DeBoer, President, ICE Cobotics U.S. “The data we receive from our autonomous scrubbers allows us to deliver cleaning performance insights and an enhanced clean to our customers at an affordable price.”
“This is what T IoT was designed for — helping enterprises solve global IoT challenges and deliver innovative solutions that make their customers want more,” said Callie Field, President, T-Mobile Business Group. “Like ICE Cobotics, T-Mobile and Deutsche Telekom share a passion for the pursuit of simple and we salute their ongoing mission to make things easier for their customers.”
To learn more about ICE Cobotics, visit www.us.icecobotics.com.
For more information about T IoT, visit www.t-mobile.com/business/solutions/iot/t-iot-global.
Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.
About T-Mobile
T-Mobile US, Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile and Metro by T-Mobile. For more information please visit: https://www.t-mobile.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005555/en/
Contact information
Media Contacts
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom